Novo Nordisk Balances Amazon Access and Generic Onslaught as Pipeline Decision Looms
Novo Nordisk’s stock is squeezed between a landmark Amazon Pharmacy distribution deal and pricing erosion from Indian generics…
Novo Nordisk Faces Generic Onslaught and Dividend Adjustment in Key Market
Novo Nordisk’s semaglutide patent expires in India, sparking generic price war. Stock hits 52-week low while trading ex-dividend,…